Skip to main content
AmigoFish

Q3 earnings roll on, FDA pushes rare disease, uniQure’s Huntington’s therapy reaches review

From BioSpace · · 23 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

The majority of the large pharmas have now reported third quarter earnings—spoiler alert: Eli Lilly made more money than anyone expected. Plus, the FDA dropped another initiative aimed at accelerating rare disease treatments; HHS greenlights the compounding of six unapproved peptides; and uniQure’s embattled gene therapy for Huntington’s disease has finally been accepted for review.

Back to BioSpace · Report a problem